SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells

Background: TP53 gene mutations are common in breast cancer and are linked to chemoresistance. p63, a p53 family member, can induce apoptosis independently of p53, representing a potential therapeutic target in TP53-mutant tumors. This study evaluated the synergistic effects of SB...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yu-Ling Kou, Yu-Jie Liu, Tzu-Chi Hsu, Kuan-Yo Wu, Sih-Tong Chen, Jing-Yan Chen, Kuan-Yu Lin, Hsiao-Hsuan Wang, Yi-Ting Cheng, Chia-Chi Chen, Bi-He Cai
Format:	Artigo
Idioma:	Inglês
Publicat:	IMR Press 2025-12-01
Col·lecció:	Frontiers in Bioscience-Landmark
Matèries:	sb431542 doxorubicin p63 tumor suppressor protein p53 mutation breast cancer drug interactions
Accés en línia:	https://www.imrpress.com/journal/FBL/30/12/10.31083/FBL45389
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!